Clinical trials
Terminated Phase 2 Myeloproliferative Disorders trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
34 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2004 | 3 |
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 2 |
| 2010 | 4 |
| 2011 | 1 |
| 2012 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 2 |
| 2023 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 34 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Incyte Corporation | 3 |
| Mayo Clinic | 3 |
| H. Lee Moffitt Cancer Center and Research Institute | 2 |
| National Cancer Institute (NCI) | 2 |
| OHSU Knight Cancer Institute | 2 |
| Alliance for Clinical Trials in Oncology | 1 |
| Barbara Ann Karmanos Cancer Institute | 1 |
| Baylor College of Medicine | 1 |
| CTI BioPharma | 1 |
| Cellphire Therapeutics, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Myeloproliferative Disorders | 34 |
| Myelodysplastic Syndromes | 17 |
| Primary Myelofibrosis | 16 |
| Leukemia | 12 |
| Leukemia, Myeloid, Acute | 12 |
| Multiple Myeloma | 12 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 10 |
| Leukemia, Myelomonocytic, Chronic | 10 |
| Lymphoma, Non-Hodgkin | 10 |
| Polycythemia Vera | 10 |
Trials
Showing 1 to 25 of 34. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.